CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects

OBJECTIVE—: Lp(a) [lipoprotein (a)] is composed of apoB (apolipoprotein B) and apo(a) [apolipoprotein (a)] and is an independent risk factor for cardiovascular disease and aortic stenosis. In clinical trials, anacetrapib, a CETP (cholesteryl ester transfer protein) inhibitor, causes significant redu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arterioscler Thromb Vasc Biol
Autors principals: Thomas, Tiffany, Zhou, Haihong, Karmally, Wahida, Ramakrishnan, Rajasekhar, Holleran, Stephen, Liu, Yang, Jumes, Patricia, Wagner, John A., Hubbard, Brian, Previs, Stephen F., Roddy, Thomas, Johnson-Levonas, Amy O., Gutstein, David E., Marcovina, Santica M., Rader, Daniel J., Ginsberg, Henry N., Millar, John S., Reyes-Soffer, Gissette
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2017
Matèries:
Clinical and Population Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5567403/
https://ncbi.nlm.nih.gov/pubmed/28729361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.117.309549
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars